Virtual symposium on “Hot topics and challenges in SBRT for oligometastatic disease”

On 30 January 2024, EORTC and the European Society for Radiotherapy and Oncology (ESTRO) collaboratively organised a virtual symposium as part of the OligoCare project. Distinguished speakers, including Daniela Greto, Giulio Francolini, Chiaojung Jillian Tsai, David Palma, and Shankar Siva, engaged in discussions on the latest evidence and clinical trials in the oligometastatic disease field, presenting insights derived from the OligoCare cohort. The symposium served as a hub for the exchange of knowledge and expertise among professionals dedicated to advancing the understanding and treatment of oligometastatic disease.

The discussions covered various topics, including the application of the TwiCs (Two-Stage Comparison) methodology in radiation oncology. The following ten key takeaways encapsulate the essence of the discussions:

  • OligoCare Research Opportunities: Partners and researchers within the OligoCare community now have the opportunity to propose and evaluate ideas with the steering committee, opening doors to exciting research prospects.

  • Patient Enrolment Milestone: The OligoCare community celebrated the recruitment of over 2500 patients, expressing gratitude for the collective effort driving crucial research forward.

  • Tailoring Treatments for Personalized Care: Emphasis on different biological doses based on tumour type and site underscored the importance of personalized care in the treatment of oligometastatic disease.

  • Safety as a Top Priority: The symposium reiterated the commitment to safety, with minimal toxicity and complications leading to SBRT-related deaths, emphasizing the paramount importance of patient safety.

  • Prostate Cancer Quality of Life (QoL): Insights revealed that QoL in prostate cancer patients remains stable during the initial 6 months of SBRT for Oligometastatic Disease, empowering patients on their cancer journey.

  • Holistic Patient Well-being: Baseline QoL comparability across tumour types emphasized the need for holistic approaches, addressing the overall well-being of patients undergoing treatment.

  • ARTO Trial Breakthroughs: The ARTO trial showcased significant advancements with improved biochemical response, progression-free survival (PFS), and time to the next systemic treatment in mCRPC OMD cases.

  • STOP Trial Insights: Results from the STOP trial clarified that standard of care (SOC) + SBRT and SBRT yield similar median PFS for oligoprogressive cancer, guiding clinicians in treatment decisions.

  • CURB Trial Impact: The CURB trial demonstrated increased PFS with SBRT + standard care, particularly in breast cancer cases, laying the groundwork for future advancements in cancer treatment.

  • SABR Insights for Lung Disease: Exploring SABR for OMD lung disease, the symposium revealed that single vs. multifraction SABR showed no significant impact on results, providing valuable insights for better decision-making in lung cancer treatment.

The EORTC & ESTRO OligoCare symposium was as a pivotal event, bringing together experts and stakeholders to advance the understanding of oligometastatic disease and pioneer new paths in radiation oncology. The video recording is now available for viewing.